Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular
benefits, but the relationship between GLP-1RA and tumors is controversial. Recently …

The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of
various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship …

There is no question that incretin-based glucose-lowering medications have proven to be
effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are incretin hormones that control the secretion of insulin, glucagon, and somatostatin to …

Aims To determine the potential association between the use of either glucagon‐like peptide‐
1 receptor agonists (GLP‐1RAs) or dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and the risk of …